Strategic focus EpiEndo is a clinical stage pharmaceutical company focused on barrier dysfunction in inflammatory conditions across airway, GI tract, and skin, presenting opportunities to partner on late-stage development or co-fund trials targeting chronic respiratory diseases and related mucosal pathologies.

Lead asset potential The lead asset glasmacinal (EP395) is an orally available macrolide with reduced antimicrobial resistance potential, offering a compelling value proposition for partnerships in anti-inflammatory airway indications and antiviral enhancement in bronchial epithelia.

Recent funding Recent convertible bond financing and new investor participation indicate growing financial backing and momentum for expansion, signaling readiness for collaboration on clinical development, regulatory activities, or international trials.

Academic collaborations Partnership with Lund University and engagement with scientific advisory leaders position EpiEndo for co-development opportunities, access to preclinical data, and credibility to attract pharma and biotech collaborators.

Market and peer context Operating with a small team in Iceland and targeting a niche but high-need segment aligns with potential for regional partnerships, contract research, and technology licensing to accelerate global reach in chronic respiratory and barrier-related inflammatory diseases.